



**ASX Announcement**

**21 August 2025**

### **Update on Indicated Pascal Supply for FebriDx®**

SYDNEY, Australia, 21<sup>th</sup> August 2025 - Atomo Diagnostics Limited (ASX:AT1) (Atomo) is pleased to note that its Pascal test cassette has performed exceptionally well in US clinical studies supporting a CLIA waiver submission for Lumos's FebriDx® test. (LDX ASX Release: Lumos announces FebriDx CLIA Waiver Application Submission, 18-08-2025).

FebriDx® has previously secured 510k clearance from the US FDA using the Pascal cassette and recently completed a CLIA waiver trial and submission to US FDA using the Pascal cassette. Atomo is extremely pleased to see that in the CLIA waiver trial that Pascal has enabled greater than 99% concordance between trained and untrained operators using FebriDx®.

In its Q3 FY25 Quarterly Report Atomo announced that the agreement for supply of Pascal cassettes to Lumos for FebriDx was amended, with the new agreement to remain in effect until 30 June 2031 and detailed committed revenues totalling US\$3.4m, based on FebriDx securing CLIA waived status.

Since the Q3 FY25 Quarterly Report, on the basis that FebriDx® using Atomo's Pascal cassette receives a CLIA waiver and that the contracted minimum order quantities between Lumos and PHASE are achieved, supply of Pascal cassettes to Lumos to meet demand under their recent six-year exclusive U.S. distribution agreement for FebriDx® with PHASE Scientific represents Pascal increased orders up to US\$6.9 million / A\$10.7<sup>1</sup> million over the first three years of the contract, with strong growth in demand anticipated in the latter years of the contract, of which Atomo will keep the market informed as required. The contract minimums remain in effect however demand

---

<sup>1</sup> AUD / USD = 0.64 as at 20<sup>th</sup> August 2025



anticipated from the supply of FebriDx, and outlined above, materially exceed these contract minimums and reflect the scale of the agreement now in place for FebriDx in the US.

Lumos previously indicated that it expects its agreement with PHASE to generate FebriDx® product sales of up to US\$313.5 million over the six-year term, assuming CLIA waiver is granted and contracted MOQ's achieved. (LDX ASX Release: Lumos Signs Pivotal US FebriDx Agreement, dated 16-07-2025).

The FebriDx® test utilises Atomo's patented Pascal test cassette to deliver improved usability and reliability in point of care settings, and Atomo is the exclusive licensor, manufacturer and supplier of the Pascal cassette to Lumos for its FebriDx® product.

Atomo and Lumos are now in discussions regarding supply of Pascal cassettes for the PHASE agreement, expected to be in addition to the revenues detailed above which relate to demand post FebriDx® securing CLIA waiver. Atomo will provide an update to the market as required under its continuous disclosure obligations. (AT1 ASX Release: Atomo secures order for Pascal worth US\$410,000 from Lumos, dated 7-08-2025).

Managing Director John Kelly said, *"We are very pleased to see demand for Pascal in a valuable long-term contract in the US market and I am delighted by the level of performance that our integrated Pascal cassette delivers to partners seeking to secure approvals for tests in CLIA waived and Self-Test markets, where ease of use and reliability are critical."*

For more information, please contact:

John Kelly  
Atomo Diagnostics  
[john.kelly@atomodiagnostics.com](mailto:john.kelly@atomodiagnostics.com)  
Phone: +61 401 922 279

*This announcement was authorised by the Managing Director & CEO.*



### **About Atomo**

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, COVID-19, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at [www.atomodiagnosics.com](http://www.atomodiagnosics.com)

For personal use only